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Some lineage-determining transcription factors are overwhelm-
ingly important in directing embryonic cells to a particular differ-
entiation pathway, such as Ascl1 for nerve. They also have an
exceptionally strong ability to force cells to change from an un-
related pathway to one preferred by their action. Transcription
factors are believed to have a very short residence time of only
a few seconds on their specific DNA or chromatin-binding sites. We
have developed a procedure in which DNA containing one copy of
the binding site for the neural-inducing factor Ascl1 is injected
directly into a Xenopus oocyte nucleus which has been preloaded
with a limiting amount of the Ascl1 transcription factor protein.
This is followed by a further injection of DNA as a competitor,
either in a plasmid or in chromosomal DNA, containing the same
binding site but with a different reporter. Importantly, expression
of the reporter provides a measure of the function of the tran-
scription factor in addition to its residence time. The same long
residence time and resistance to competition are seen with the
estrogen receptor and its DNA response elements. We find that
in this nondividing oocyte, the nerve-inducing factor Ascl1 can re-
main bound to a specific chromatin site for hours or days and
thereby help to stabilize gene expression. This stability of tran-
scription factor binding to chromatin is a necessary part of its
action because removal of this factor causes discontinuation of
its effect on gene expression. Stable transcription factor binding
may be a characteristic of nondividing cells.
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Biochemical experiments have concluded that the dwell timeof a transcription factor on its specific DNA site is re-
markably short, on the order of seconds (1–5), and may involve
oscillation of binding. It would be of considerable interest if the
dwell time for some kinds of transcription factors were found to
be enormously longer under certain circumstances. This is es-
pecially so if the duration of transcription factor binding to DNA
is required for some kinds of normal cell lineage progressions
and for the stability of cell differentiation. The results described
here give evidence of a very long dwell time by the same mole-
cule for a cell lineage–determining factor. This helps us to un-
derstand the mechanism of action of a transcription factor that
guides cell fate and stabilizes cell differentiation.
We distinguish the dwell time of a factor at its site on DNA or
chromatin from the site occupation time by a factor. The dwell
time means the length of time for which the same molecule of a
factor remains bound to its specific binding site. The site occu-
pation time is the time for which a binding site is occupied by the
same kind of transcription factor but not necessarily by the same
actual molecule.
Some transcription factors are of great importance in directing
embryo cells into their intended differentiation fate. The first
example of this was MyoD, which has the ability, when overex-
pressed, to switch the fate of most kinds of cells into muscle (6).
Subsequently, other examples of lineage-determining factors
were and include Ascl1, a major neurogenic inducer in embry-
onic cells and one which causes cells to follow a neural differ-
entiation pathway (7, 8). It can also make adult cells of different
kinds become neural (9), like MyoD does for muscle (10). Ascl1
is known to bind to a specific DNA sequence, CANNTG (11,
12), and is assumed, like the glucocorticoid receptor, to contin-
ually bind and dissociate from its DNA binding site, raising the
question of its mechanism of action. We find here that the site
occupation and dwell time of Ascl1 can be much longer than has
been generally believed. This may enable this factor to both
initiate and stabilize a differentiated state and so give new un-
derstanding of the mode of action of a transcription factor in
some kinds of cells.
Results
Experimental Design. This design needs explanation and valida-
tion. The residence time of a transcription factor determining
cell fate is tested by induced gene response to a transcription
factor and hence by function. The procedure for this use of
oocytes is as follows (Fig. 1A). We inject messenger RNA
(mRNA) encoding a transcription factor, in this case the neu-
rogenic factor Ascl1 (14), into the cytoplasm of a Xenopus oo-
cyte, allowing the encoded protein to reach a desired
concentration in the oocyte nucleus or germinal vesicle (GV).
We then inject plasmid DNA, which has binding sites for the
factor and an expression reporter, directly into the oocyte GV, so
that it is immediately delivered to the nuclear environment of the
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Ascl1 protein. We also use mRNA for a membrane-bound GFP,
coinjected with the Ascl1-binding reporter DNA (p1008), to
identify successfully injected oocytes (15, 16). The next day we
assay each DNA-injected oocyte for expression of its reporter as
an indication of the functional binding of the transcription factor
to its specific DNA binding sequence. The next step is to inject
plasmid DNA into the same already injected oocytes so that it
can compete for any of the same factor that may have been re-
leased from the first plasmid DNA. If the residence time of the
factor is short, the second DNA should compete for it and so
cause expression of the second DNA. The extent to which the
second DNA is expressed should therefore provide a measure of
the residence time of the factor on the first DNA.
To what extent does this experimental procedure represent
normal transcription in oocytes and in other cells? The injected
DNAs are soon converted into nucleosomed chromatin, using
the large store of oocyte histones (17–20) to which the factor
binds, but are not integrated into the oocyte’s chromosomal
DNA. Successful injection of template DNA into the oocyte
nucleus is routinely accomplished in about 80% of attempts. We
consider the injected nonintegrated plasmid DNA/chromatin to
be the equivalent of the extrachromosomal nucleolar DNA al-
ways contained in a normal Xenopus oocyte GV (21). A typical
injection of plasmid DNA (p1008) at 100 pg/oocyte amounts to
injecting 107 molecules, and hence, this number of test genes is
not much more than the 106 endogenous extrachromosomal ri-
bosomal DNA genes always present and transcriptionally very
active in uninjected Xenopus oocytes. We know that both the
E-box and Pou domains in p1008 DNAs are important for the
transcription and translation of Ascl1 and its reporter (22)
(Fig. 1B). In typical trials, plasmid transcription is controlled by
the Ascl1 binding sites (E-box and Pou domains), so that assay-
able luciferase proteins are expressed. Plasmids lacking the
E-box and Pou domains have a background expression of nearly
1,000-fold lower.
For many experiments we use the Ascl1 binding reporter DNA
plasmid p1008 FF, which causes a strong expression of a stable
Firefly luciferase. Therefore, the luciferase activity that we re-
cord is the one which has accumulated from the time of DNA
injection to the time when samples are frozen for analysis. In
most cases this time is between 1 and 3 d. In other experiments
we use the same plasmid with a very short half-life luciferase,
namely, p1820 FF, but with exchanged reporter and regulatory
sequences. Using cycloheximide to arrest protein synthesis, we
find that the luciferase encoded by p1820 FF has a half-life of
about 1.5 h as found by others (23) in oocytes, compared to
about 50 h for an average protein (24). Using this DNA, we
therefore see only the last 1 to 2 h of luciferase expression, even
if the whole oocyte incubation period is up to 3 d. The half-life of
luciferase mRNA synthesized in oocytes is about 5 h at 16 °C
(α-amanitin assay). DNA p1820 and its reporter FF are not
transcriptionally activated and expressed unless mRNA encoding
Ascl1 is present. The reporters FF and R (see Fig. 1B) are easily
distinguishable and not overlapping.
A very important aspect of this oocyte assay is that the binding
of Ascl1 is assessed by its functional effect on gene expression.
Fig. 1. Experimental design. (A) The sequence of injections on living oocytes of Xenopus. The normal injection volume is 14 nL, aimed for the cytoplasm
(mRNA) or the nucleus (GV). Nucleic acids were made up in water for injection. (B) DNA plasmid composition. The various plasmids used are derived from
PGL4.28 (Promega). P1008 was provided by A. Philpott (Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, UK) (ref. 25). The base
pairs marked in red had been mutated as shown for the E-box and Pou sequences. (C) The mRNAs shown cause a substantial increase in the abundance of
transcripts from the E-box–Pou–E-box domain of p1008 DNA. Ascl1 SA is a variant of mouse Ascl1 in which alanines have been mutated to serines. *P = 0.001;
**P = 0.009. (D) Different amounts and kinds of Ascl1 mRNA induce a huge increase in Firefly expression of p1008 DNA. *P = 0.005; **P = 0.007. (E) The
reporters FF for p1008 and p1820 respond strongly and independently to Ascl1 mRNA. The reporter Renilla responds similarly to DNA p7815 R. (F) Different
kinds of mRNA induce specific reporter responses. Neurogenin (orange) has almost no effect and Sox2 (black) of mice and no effect at all on Firefly expression
(red). Error bars represent the SEM in three independent experiments (n = 3).




















Most other assays for transcription factor association with a
binding site measure binding visually or biochemically rather
than by function.
Characterization of the System. The composition and expression of
our p1008 and p1820 plasmid DNA are particularly important
for the work described here. The DNA sequence to which the
transcription factor Ascl1 binds is an E-box–Pou-E–box motif,
this CANNTG sequence being characteristic of several tran-
scription factors, including Ascl1. The rest of the plasmid DNA
(Fig. 1B) contains 12 CANNTG sequences (13, 25). Moreover,
mutations in these two E-box parts of our p1008 plasmid reduce
expression of the FF reporter down to about 4%, while the
mutation of its Pou domain alone reduces its Ascl1-induced ex-
pression down to 80% (Fig. 1B). This means that this single
DNA region is almost wholly responsible for the Ascl1-induced
expression which we see. This is in contrast to many other
transcription factor binding sites in DNA, where there are many
such sequences in the genomic DNA, at least several of which
may be important for expression induced in normal development
(26). In p1008 and p7815, there are 12 CANNTG sequences, and
we do not know whether one or many of these are normally
required for the downstream effects of Ascl1 to be seen.
When we assay injected oocytes for transcripts from plasmid
DNA p1008, we see an abundance of FF luciferase transcript
within a day of DNA injection (Fig. 1C), and most of this RNA is
dependent on a previous cytoplasmic injection of Ascl1 mRNA,
as well as being sensitive to α-amanitin. Ascl1 and MyoD share a
very similar binding sequence (22). In subsequent experiments
we have chosen to assess our results by the amount of induced
Firefly-tagged activity because this gives a measure of Ascl1-
induced gene expression at the level of protein. The injection
of mRNA encoding a transcription factor and plasmid DNA
containing its binding region is followed by a very large increase
in reporter luciferase activity of 10 to 100 times above the level in
oocytes not injected with mRNA (Fig. 1D). Both FF and R re-
porter expression give a strong response, and there is no overlap
between these two reporters (Fig. 1E). These reporters do not
respond to injection of mRNAs encoding unrelated transcription
factors, including neurogenin (Fig. 1F). In the absence of
mRNA, there is a low level of FF luciferase expression from
injected DNA, but this is usually only 1 to 10% of the level of
luciferase seen after Ascl1mRNA when large amounts of mRNA
are injected (Fig. 2A).
With large amounts of Ascl1mRNA both reporters, FF and R,
are well expressed (Fig. 2B). Enough Ascl1 protein is generated
to allow transcription of sequentially injected reporter plasmids.
The induced Ascl1 protein concentrates in the GVs of recipient
oocytes when it settles to a steady concentration for a few days
(Fig. 2C). The localization of Ascl1 protein in the GV is en-
hanced by the use of a nuclear localizations sequence (NLS)
signal in the Ascl1 mRNA (Fig. 2D). To confirm previous work,
we have checked that injected DNA becomes quickly associated
with histones (Fig. 2E). The order of injection of the two DNAs
(FF or R) does not affect the strong response of the DNA to
mRNA injection (Fig. 2F). In the absence of mRNA injection
there is a low level of FF luciferase from the injected DNA, but
this is usually only 1 to 10% of the level of luciferase seen after
Ascl1 mRNA when large amounts of mRNA are injected
(Fig. 2A). After mRNA injection into oocytes, Ascl1 protein soon
accumulates in oocytes, where it settles to a steady concentration
for a few days. Western analysis of isolated GVs has also enabled
us to show a steady concentration of Ascl1 protein in the GV of
injected oocytes over 3 d and that the concentration of Ascl1
protein in the GV is 10 to 20 times above that in the cytoplasm
(Fig. 2C).
To determine the duration of DNA site occupation by a
transcription factor, we subsequently inject a second plasmid
DNA with the same transcription factor binding site to act as a
competitor, but with a different reporter. This is p7815 with a
Renilla reporter (Fig. 1B). If the Ascl1 factor is not stably bound
to the first plasmid DNA, it will be released and then bound by
the second (competitor) DNA, especially if a competitor DNA is
in a high concentration and if the concentration of Ascl1 mRNA
is limiting. We need to be sure that both the test reporter DNA
plasmid and the competitor plasmid respond similarly to over-
expression of the mRNA that encodes Ascl1. To further char-
acterize this experimental system, we also want to be sure that
oocytes that have already received a cytoplasmic injection of
mRNA and a GV injection of DNA can, nevertheless, transcribe
and express a second GV injection of another DNA a day later.
We initially tested this with a first injection of competitor DNA,
followed by reporter DNA, to see if, as expected, the reporter
DNA expression is not precluded by the first injected DNA. In
these experiments, we used a large amount (2 ng or more per
oocyte) of Ascl1-encoding mRNA. We see that expression of the
second DNA (p1008 or p1820) increases substantially as a high
level of mRNA is supplied (Fig. 2B) to give these conditions of
excess mRNA. This excludes the possibility that under these
conditions, a second DNA is either degraded or converted into a
nonfunctional form.
The conclusions from many experiments, which gave very
similar results, are as follows: 1) Two sequential injections of
DNA into the same GV can result in meaningful transcription of
two plasmid DNAs, as long as there is a large amount of Ascl1
protein from injected mRNA so that the two DNAs are not in
competition. 2) The second DNA injection in these experiments
normally includes a GFP membrane-associated plasmid DNA
which shows that the success of GV injection is generally over
80% and enables injections that miss the GV to be excluded. 3)
The overall conclusion from these experiments is that oocyte
injection provides a valid assay for a functional transcription
factor effect on its DNA binding site and on the consequential
gene expression. It is important to appreciate that the amount of
mRNA in these initial experiments was large enough for this not
to be limiting (Fig. 2B). Therefore, even when all Ascl1 binding
sites on the first DNA are occupied by Ascl1, there will still be
enough of the Ascl1 factor in the test oocytes to permit some
transcription and expression of the second injected
reporter DNA.
Competition Experiments.
Limiting mRNA.We now need to make the amount of Ascl1 protein
limiting to create competition between the two DNAs for the
Ascl1 factor derived from injected mRNA. At low amounts of
injected Ascl1 mRNA, reporter Firefly luciferase activity in-
creases in proportion to the amount of mRNA injected (Fig. 3A),
and a further increase in the amount of Ascl1 mRNA makes very
little difference to the induced FF expression. In most batches of
oocytes, 1 ng of Ascl1 mRNA or less behaves as a limiting
amount and saturates subsequently injected DNA. Increasing
amounts of injected DNA give a small, but not proportionate,
increase in the amount of induced luciferase reporter expression.
The amount of mRNA needed for a limiting level varies between
batches of oocytes but is generally <4 ng/oocyte (Fig. 3A).
Expression DNA first. Under the conditions of 490 pg mRNA/oo-
cyte, we injected p1820 FF as the first DNA at 120 pg/oocyte and
then, 1 d later, injected a second DNA, p7815 R, at increasing
concentrations (Fig. 3B). In further tests, we increased the du-
ration of incubation after the second DNA to up to 48 h from the
time of the first DNA (Fig. 3C). In Fig. 3D, we summarize the
results of 17 independent experiments. Note that the scale in
Fig. 3 B–D is logarithmic to draw attention to the magnitude of
the difference between control and experimental samples. In all
cases, we see an extraordinary stability of Ascl1 binding to its
DNA or chromatin region and no evidence of its dissociation of

































Ascl1 from DNA or chromatin within 2 d and under conditions
of very large competition.
Confirmation by inverted order of injected DNAs. To verify the over-
whelmingly dominant effect of the first DNA over a subsequent
DNA, we inverted the order of addition of DNAs (Fig. 3E). We
injected a first DNA (tagged with Renilla) followed by increasing
amounts of a second DNA FF. We saw no change in expression
of the first DNA. This is true even with a huge excess of the
second DNA concentration (10,360 pg/oocyte) and an in-
cubation time of 24 h after the supply of competing DNA
(Fig. 3F). Therefore, again, the second DNA (p1008 FF) in ex-
cess is not able to increase its own expression or to change ex-
pression of the first DNA (p7815 R). This means that the Ascl1
transcription factor did not dissociate to any extent from the
p1008 DNA since any that had been released would have been
taken up by the first DNA and increased its expression.
We emphasize that in the design of these experiments, we do
not require expression of the second competitor DNA; it has
only to be able to bind any available Ascl1 protein, including that
which might be released by a short dwell time on the first in-
jected DNA. Nevertheless, we want to be sure that a second
injected DNA is in a functional state. It could be imagined that
when it does not compete with a first DNA, a second DNA could
be converted, directly or indirectly, to a noncompetitive state.
We have tried therefore to rescue expression of the non-
competing (second) DNA as follows (see Fig. 4A).
Rescued expression of the second DNA. We prepared oocytes with
limiting Ascl1 mRNA to 210 pg/oocyte. This was followed by
injection of a first DNA, Renilla (p7815 R), which was expressed.
This was then followed by a second DNA injection of p1820 FF.
As found before, this second DNA was poorly expressed because
of the preceding (p7815 R) DNA, in this example, FF values of
1,346 compared to 6,900 for no first DNA (Fig. 4A, second
column). However, when we supplied a second injection of Ascl1
mRNA (2.2 ng/oocyte) at the same time as the second DNA so
that Ascl-1 protein was no longer limiting, this increased ex-
pression of the second (repressed) DNA p1820 FF from 1,346 to
13,427, an increase of 10 times (Fig. 4A, second column versus
fourth column). An independent repeat of this experiment with
different amounts of injection gave a similar result (Fig. 4B).
Therefore, we have been able to enforce expression of a second
DNA that is repressed by competition, using an increased supply
of Ascl1 mRNA. Two further such experiments gave a similar
result. Thus, we find that when a second DNA is not well
expressed, following an injection of the first DNA, it is able, with
high doses of extra Ascl1 mRNA, to be bound by expressed
Ascl1 protein.
The rescuing effect of the second Ascl1 mRNA injection is not
complete. It reaches about half the maximum level that can be
reached by Ascl1-induced FF expression if there had been no
competitor DNA at all. If we try an RNA rescue experiment
using a complete GV extract including all of the numerous
transcription factors present in a normal oocyte GV, this can also
have some rescuing effect.
DNA Response Element Integrated into Chromosomal DNA. We now
ask whether the stable occupation of a binding site on DNA or
chromatin by a transcription factor as observed in our
Fig. 2. Characterization of gene expression induced by Ascl1 mRNA in DNA-injected oocytes. (A) The background level of luciferase in oocytes that received
DNA but no mRNA was 1 to 10% of the mRNA-induced level. (B) High levels of injected Ascl1 mRNA are sufficient to induce expression of a second injected
DNA. (C) Ascl1 mRNA-encoded protein concentrates in the GV of injected oocytes and remains at a high level for 3 d. (D) A nuclear localization signal in Ascl1
mRNA helps to increase GV localization injected oocytes. (E) Injected DNA soon becomes associated with histone from injected histone mRNA. (F) The order of
addition of DNA (FF or R first or sequential) gives the same conclusion: The first DNA dominates over the second. Error bars shows SEM for (n = 3) where
applicable.




















extrachromosomal plasmid DNA experiments above is also true
of the same DNA binding sequence integrated into chromo-
somal DNA. The experimental design is similar to that used in
our previous plasmid experiments (Fig. 3B) where DNA was
transfected. We transfected the whole E-box–Pou–E-box re-
sponse element from plasmid DNA p1008 FF into chromosomal
DNA of a mouse embryonic fibroblast (MEF) cell line com-
monly used in our other oocyte experiments. We transplanted
these MEF nuclei carrying a transfected E-box–Pou–E-box DNA
for Ascl1 binding into oocytes already expressing the Ascl1
transcription factor after mRNA injection, as in our plasmid
experiments. The enhancement of p1008 FF expression in
transplanted nuclei shows the same 25-fold increase over
non-mRNA-injected samples, as is seen in equivalent plasmid
DNA experiments. We then carried out competition experiments
as described above for plasmid DNA. The same conclusions are
reached. The competitor plasmid DNA p7815 causes no de-
tectable reduction in Firefly luciferase encoded by the DNA-
transfected injected nuclei (Fig. 4C). Remarkably this is even
true if the amount of competing DNA is increased from 102 to
106 (Fig. 4C). This result was seen at both 24 and 48 h after
injection of competitor DNA (Fig. 4C). We conclude that a
chromosomally integrated Ascl1 binding site behaves the same as
in our extrachromosomal plasmid DNA experiments; in each
case the duration of the transcription factor binding site occu-
pation is remarkably long and resistant to a large excess of
competitor DNA. Again, there is no evidence for the release of
bound Ascl1 protein from DNA or chromatin DNA, even after
many hours.
Protein Competition. Since we have reached an unexpected con-
clusion different from that of previous work, using an un-
conventional assay, we have sought to test our conclusion by
another procedure (Fig. 4D). This involves a protein competition
experiment. We cannot use the same DNA-encoded FF reporter
assay as above because a competing Ascl1 protein would also
induce expression of the same DNA Firefly reporter and so
obscure any competition effect that might exist. We have
therefore used chromatin immunoprecipitation (ChIP) analysis
to determine the binding of Ascl1 protein to its DNA binding
site. We start with an injection of Ascl1-GFP mRNA, which is
soon translated into Ascl1 protein. After nuclear injection of
DNA p7815R into the GV, we then inject mRNA for an Ascl1
tagged with HA (Fig. 4D) to compete for binding with the first
injected Ascl1-GFP mRNA and ask whether, by ChIP, an excess
of Ascl1-HA can displace the other already bound Ascl1-GFP.
This would happen only if the first bound Ascl1-GFP protein
were to have a short dwell time on its DNA. We see a reduction
in Ascl1-GFP binding compared to no competition at all, but
only by 30%, and this is with a 10-fold excess of competing RNA
and for a 23 h incubation period (Fig. 4E). However, this could
be due to an unspecific effect of a large amount (10 ng) of
competing RNA. To test this, we have competed the first Ascl1-
GFP with an mRNA encoding the completely unrelated xklf2-
Fig. 3. Lack of competition for sequentially introduced DNA binding sites. (A) Fifty picograms of plasmid DNA are nearly saturated by 4 ng of Ascl1 mRNA. In
most samples of oocytes, 500 pg to 1 ng of Ascl1 mRNA per oocyte containing 210 pg of p1820 DNA was sufficient to ensure that the synthesized protein
limits the amount of luciferase reporter seen. Beyond this level, no further reporter expression is obtained by injecting a further amount of DNA or RNA. (B)
Increasing the amount of a second competitor DNA up to 3,360 pg/oocyte does not increase the amount of the first DNA’s reporter (p1820 FF). (C) A lack of
competition is seen by a second DNA if the duration of incubation is prolonged for 2 d after the first injection. (D) Summary of results from 17 frogs in
different experiments, showing that no significant reporter expression is obtained from a second injection of DNA. The synthesized DNA was injected at 0.2 to
12 ng/oocyte. (E) After Ascl1 mRNA at 210 pg/oocyte, we inject competitor DNA 7815R, also at 210 pg/oocyte. The next day, expression p1820 FF is injected at
concentrations from nil to 840 pg/oocyte. (F) The amount of expression DNA p 1820 FF is the same in all samples, but the amount of p7815R as first DNA, as a
competitor, shows the expected increase.

































HA, which has shown strong protein expression in our other
unrelated experiments. We now see a reduction in Ascl1-GFP
binding, but only by 20% (Fig. 4E), and this is only 10% different
from competition with the specific competitor Ascl1-HA.
Therefore, the main effect of this DNA binding experiment re-
sults from a high amount of mRNA. We have checked that the
amount of competitor Ascl1-HA protein in this experiment was
as high as expected from its high mRNA injection.
We point out that even if there is any real difference between
the DNA and protein competition results, the main conclusion is
the same. It is that a dwell time of Ascl1 protein in these living
cell experiments is very long indeed compared to previous results
of others with the glucocorticoid receptor.
A Long Residence Time Is Also Seen with the Estrogen Receptor. We
pointed out in the introduction above that previous work in this
field has been done with receptors which govern gene expression
and that need to change frequently according to conditions;
these include the estrogen receptor (3, 27, 28). We now ask
whether the long residence time reported for Ascl1 in oocytes is
also true of the estrogen receptor when tested in oocytes by a
competition assay.
We used mRNA for an estrogen receptor ER1 and estrogen
response elements tagged with Firefly or Renilla (Fig. 5A). The
first DNA was injected 20 h after the mRNA; the second
(competitor) DNA was supplied in excess 1 d after the first
DNA, and samples were collected 24 to 48 h after the second
DNA. We also find that in an experimental design similar to that
carried out for Ascl1, the provision of an estrogen reporter ele-
ment elicits an enormous enhancement of estrogen reporter el-
ement expression (Fig. 5B). Estrogen does not need to be added.
We find that a second DNA is minimally expressed if it is in-
duced a day after the equivalent, but differently tagged, first
DNA (Fig. 5C). This result is seen whether the Firefly- or
Renilla-tagged DNA is injected first (Fig. 5C). We find that a
large amount of competitor DNA does not reduce expression of
Fig. 4. Rescue of nonexpressing second DNA. (A) It starts with the usual injection of Ascl1 mRNA at 210 pg/oocyte. After 8 h, a GV injection of the first DNA
(p7815R) is made. Twelve hours later, another GV injection of DNA is made, this time of p1820 FF at 210 pg/oocyte, as the second DNA. As expected, this
second DNA is poorly expressed because of the earlier injection of the first DNA. However, if a second injection of Ascl1 is now made with 2.2 ng/oocyte to
raise the level of Ascl1 protein above the limiting amount, it now causes a strong expression of the second DNA. This increased FF values from 1,346 to 6,900.
This compares to the high initial level (13,427) of expression of p1820 FF DNA if the reexpression of the previously expressed second DNA (p1820 FF) has now
been raised by five times had been no initial expression of it by 7815R. (B) Confirmation of second DNA rescue due to a further supply of Ascl1 mRNA. The
experimental design is similar to that in A, except that a greatly increased amount of p1820 FF was introduced. Even now there is no indication of release of
Ascl1 from the first DNA, to which it seems to be stably bound. The second injection of mRNA II causes a large increase in expression of the second (repressed)
DNA. After Ascl1 mRNA and subsequent competitor p7815R DNA, both at 210 pg/oocyte, p1820 FF was injected 20 h later at the increasing picogram amounts
shown. FF was analyzed 24 or 26 h later (the two time point values have been combined). The increasing amount of the second (p1820) DNA does not reduce
the response of the initial competitor DNA expression (red). (C) Transplanted nuclei with an integrated E-box–Pou–E-box DNA sequence. One day after nuclei
injection, p7815 Renilla competitor DNA was injected into the GV in different amounts. Thirty-six hours after that luciferase, FF or R, was scored. The figure
combined with the experimental design shows the luciferase values for FF were about the same independent of additional competitor DNA ranging from 0 to
106 molecules per oocyte GV (Fig. 5A). (D) Protein competition design; two differentially tagged Ascl1 proteins compete for the same binding site. (E) Using
two kinds of proteins together with ChIP analysis shows occupation of the Ascl1 binding site in DNA by each kind of protein competitor. Using p1008 FF as a
competitor, we see a reduced binding of it to DNA down to about 70% of the high competitor level. If we use Xklf2 mRNA to compete with the Ascl1 mRNA,
we see a reduction of binding from 100 to 80%. Therefore, the binding of Xklf2 competes almost as well as Ascl1 for the binding site on DNA. The competitive
binding of Xklf2 is therefore not competing directly with Ascl1 mRNA.




















the first DNA even though it could do so without its own ex-
pression. Thus, the reporter expression of the first DNA is not
reduced by the coinjection or not of a second DNA (Fig. 5C).
We conclude that the long residence time and long duration of
resistance to DNA competition for an estrogen receptor are
similar to those for the Ascl1 receptor. There is therefore some
special characteristic of an oocyte or its components which sta-
bilizes the binding of a receptor to give a very long duration of
induced gene expression.
The Continuing Presence of Ascl1 Is Required for Its Induced Stable
Gene Expression. Following the conclusion that Ascl1 has an un-
expectedly long dwell time on its chromatin, the next key ques-
tion is whether this is of functional importance. We need to ask if
the continuing presence of Ascl1 is required for its long-term
stable effect on induced gene expression. We consider the pos-
sibility that Ascl1 is no longer present and that its stable effect on
chromatin is taken over by another mechanism. The most direct
test of this question is to remove Ascl1 after its stabilizing effect
has been established and to assess the binding of Ascl1 protein by
ChIP analysis to check that it has been removed. If so, does this
reduce the suppression of a second DNA and hence show that
the long dwell time that we find is part of the function of the
transcription factor? We have been able to do this by making use
of the auxin-dependent degradation procedure of Tan et al. (29)
and Natsume et al. (30). Oocytes were prepared by the injection
of Ascl1-HA-AID mRNA, followed the next day by p1008 FF
DNA (Fig. 5D). On the following day, auxin was added to the
oocyte medium. Soon after that, competition plasmid DNA
(7815R) was injected into the GV, and a few hours later samples
were collected for ChIP analysis. The Western results, in Fig. 5E,
show that the Ascl1 protein was eliminated after auxin treatment.
In the same samples, Firefly expression was also reduced to a
negligible level compared to the nil-effect no-auxin controls and
was not reduced at all when a nondegradable Ascl1 was used
(Fig. 5F). We therefore see that the induced expression of DNA
+ FF is dependent on the continuing presence of Ascl1 and that
its stabilizing effect, resistant to competition, is not replaced by
another mechanism.
We conclude that the presence of the Acl1 transcription factor
is required for its long-term and stable gene-inducing effect. This
provides a functional test for the long-term and site occupation
stability of the Ascl1 transcription factor bound to chromatin.
Discussion
The bottom line of this work is that the early bird catches the
worm (31). We find that in a nondividing cell, two transcription
factors that bind to their specific DNA sites can remain for
several hours or days and that this largely resists competition
from similarly specific DNA sequence (or chromatin). This gives
insight into the mode of action of a transcription factor. This
Fig. 5. An estrogen receptor induces a very strong and stable expression of estrogen reporter gene expression. (A) Design of experiment. Estrogen response
mRNA was injected at 210 pg/oocyte. One day later, estrogen response element DNA at 210 pg/oocyte, tagged with either FF or R, was injected into the GV.
One day after that single oocytes were assayed for FF or R fluorescence. (B) Estrogen mRNA gives a very strong response if followed by estrogen response
element DNA. Thus, estrogen response element tagged with FF increased by 106-fold (red), and that tagged with R increased by about 100-fold (green). The
first and second columns show incubations for 48 h between mRNA injection and assay; for the fifth and sixth columns, the incubation period was 72 h. (C) An
estrogen receptor bound to its estrogen reporter DNA resists competition by DNA was a differently tagged reporter. The percentage values given show that
the second DNA (whether tagged by FF or R) gives only a 5% expression compared to the same DNA injected first. The same effect as for Ascl1 is seen:
Whichever DNA is injected first dominates over the second DNA. (D) A functional necessity for persistent Ascl1 protein on E-box chromatin: auxin depletion of
Ascl1 protein. The design of the experiment is as follows: Oocytes were injected with 1.0 ng Ascl1-3HA mRNA. The next day, 210 pg of p1008 DNA were
injected, and 1 mM auxin was added to the medium. (As a negative control, Ascl1-HA mRNA [no AID] was included.) Oocytes were processed for Firefly
analysis. The results show that both Ascl1-HA and Ascl1 AID were strongly expressed 72 h after the first mRNA. (E) Western analysis to show auxin depletion of
protein. Injected oocytes were separated in oil into GVs and cytoplasms; groups of 10 oocytes were then frozen and analyzed for Western blot procedure. (F)
Complete removal of protein by auxin is seen. Injected oocytes were analyzed as in previous samples for FF values.

































result is very different from the common view that transcription
factors have very short residence times of seconds or minutes.
For a number of years, Hager and colleagues have used many
different methods to estimate the time the glucocorticoid re-
ceptor remains bound to its DNA binding sequence. The dwell
times they have found are surprisingly short, namely, from less
than 1 s to a few minutes (2, 27, 28, 32–37). Work with the es-
trogen receptor has given similarly short times. In accord with
this finding is the oscillatory behavior of Ascl1 expression in
proliferating neural progenitor cells (38). Most recently, very
short dwell times were found for factors that regulate gene ex-
pression in early rapidly dividing Drosophila embryos. In these
cases genes need to be able to respond rapidly to changing
metabolic conditions as in embryos (37). Using a gel shift dis-
sociation assay, Fong et al. (12) found a binding time of 2 to
3 min for MyoD (CAGGTG) and NeuroD (CAGATG) in cul-
tured mammalian cells. One of the longest dwell times described
is that of the binding to the heat shock gene in differentiated
Drosophila cells, where a replacement time of 1 h was seen (39).
Individual transcription factor components can also exchange
very rapidly, such as TFIID (40). The results reported here are
clearly not in accord with this previous work, which was mostly
done with dividing and proliferating cells. The dwell time in our
experiment is hours, or even days, and is seen even when a huge
excess of a competitor is directly introduced into a nucleus.
The idea of a long residence time for a transcription factor and
resistance to competition was already discussed many years ago
in the widely appreciated work of Brown and colleagues (41–43)
using an entirely different system from what we describe here.
The system used by Brown and colleagues was an in vitro tran-
scription of 5S ribosomal genes by RNA polymerase III. In vitro
transcription is successful using RNA pol III, but no in vitro
reinitiating transcription by pol II has been described, though it
does take place in living, injected Xenopus oocytes, which also
give accurate transcription with RNA pol III (44). In Xenopus
oocytes, there are 20,000 genes that encode the oocyte-specific
5S ribosomal gene, and these are actively transcribed in oocytes
but not at all in somatic cells, whose 5S ribosomal gene tran-
scription is undertaken by 600 somatic genes (45). It was sug-
gested that the nontranscription of the oocyte 5S genes could be
explained by a repression effect of histone with a differential
binding affinity of the transcription factor TF IIIA for oocyte
versus somatic genes (43).
How can we account for this difference between our results
and those described before? DNA injection in Xenopus oocytes
was used, long ago, to find some competition between two dif-
ferent kinds of DNA in induced gene expression (25, 46, 47). But
this work does not relate to the mode of action of identified
transcription factors. The most obvious difference is in the assays
made. Previous work concentrated on transcription factor bind-
ing, whereas our results measure expression induced by the
transcription factor. Expression seems to us most relevant for
cell lineage and cell fate decisions. This difference does not, of
course, explain the very short dwell times seen in previous work.
The most likely explanation is by cofactors which could bind
close to Ascl1 (Fig. 6A). However, another possible explanation
for this (unexpectedly) long dwell time and resistance to com-
petition in our DNA injection experiments would be for the first
injected DNA to become associated with another nearby non-
chromosomal complex, where it could take up the limited supply
of Ascl1 protein, so that there would not be enough of this
protein to give transcription of a second injection of DNA
(Fig. 6B). For example, transcription complexes in amphibian
oocytes are believed to be in liquid phase–separated complexes
(48, 49). Support for the idea that an Ascl1 chromatin could be
subject to phase separation comes from our finding that the in-
jection of adenosine triphosphate (ATP) with the second DNA
has the strong effect of making it well expressed in a competition
test (Fig. 6C). Hayes et al. (49) pointed out that ATP has both
hydrophilic and hydrophobic properties and could therefore in-
terfere with phase separation. Future work will explore the likely
role of a cofactor, phase separation, or both in stabilizing Ascl1
in chromatin.
A very interesting possibility is that there are two modes of
transcription factor binding, namely, one for short-term binding
in dividing and proliferating cells, including oscillation (5, 38,
50), and the other for stable gene expression in nondividing
(including oocytes and adult) cells. Stable binding could help to
secure long-term gene expression and the differentiated state of
cells. It is an attractive aim to try to identify any cofactors that
can stabilize transcription factor binding. An important early
paper (51) discussed some general transcription factor
principles.
Materials and Methods
Xenopus oocytes. Xenopus oocytes experiments were approved by the Uni-
versity Biomedical Services at the University of Cambridge and compiled with
UK Home Office guidelines (Animal Act 1986). The frogs used to supply
oocytes were reared from fertilized eggs in our laboratory. The oocytes are
taken from the ovary under terminal anesthesia. After subcutaneous (s.c.)
injections of MS222 (methane sulfonate) frogs are kept on ice while fully
anesthetized, and the ovary is then removed. The frogs do not recover from
the terminal anesthesia.
Defolliculation of oocytes is required before they can be injected. This is
done by incubating small groups of oocytes in Liberase (research grade
supplied by Roche) for 2 h at room temperature. The individual oocytes retain
one inner layer of follicle cells but no blood vessels or blood cells. They are
then incubated in modified Barth saline solution (52) overnight with 0.1%
bovine serum albumin (BSA) in the medium. The BSA helps to reduce the
potentially damaging effect of the Liberase solution on the oocytes. The few
dead oocytes are removed before injection. Before cytoplasmic injections,
material is deposited equatorially. For germinal vesicle injections, a needle is
introduced at right angles to the surface of the animal pole. The success of
injection material into the germinal vesicle of an oocyte is about 80%. To
monitor the success, we inject a membrane GFP encoding plasmid DNA to-
gether with the rest of the sample into an oocyte GV (2, 37) Oocytes suc-
cessfully injected into the GV are seen as bright green fluorescence on the
whole oocyte the day after injection. For GV injection, see below in Oocyte
GV Injection (7).
Equipment. Glass needles are pulled out by machine, and the tips are given a
sharp point and smooth opening using a microforge constructed in our
laboratory (53). The opening of an injection needle is about 5 μm
in diameter.
Culture Medium. We use Modified Barth’s Solution (MBS) saline solution (52)
for this supplemented with 0.1% BSA. Injected oocytes are cultured at 16 to
18 °C.
DNA Constructs. We inject plasmid DNA at the stated concentrations. The
various constructs we use are based on PGL 4.28 (Promega). Formost purposes
we use p1008 with a C-terminal Firefly reporter. In some cases the Firefly
reporter is replaced by a Renilla reporter. Plasmid p1008-SA has seven serines
in the parental DNA replaced by alanines. The DNA for injection is in a
double-stranded circular form. Constructs for the estrogen work were do-
nated by J. Carroll (University of Cambridge, Cambridge, UK), from whom
further information can be obtained (Jason.carroll@cruk.cam.ac.uk). The cell
line with an E-box–Pou–E-box integration appears to have only one in-
tegration site as a result of selection during the preparation of this cell line.
Nucleic Acid and Protein Extraction.Nucleic acid and protein extraction is done
by our standard procedures, as described by Halley-Stott et al. (15).
Statistics. In most of this work the effects we see are very large; for example,
we see a 100 times larger effect over background than whenmRNA or DNA is
omitted (so we do not see the need for statistical analysis); see, for example,
Fig. 2F. The statistical tests for Fig. 2 E and F were Student’s t test and two-
way ANOVA.
Oocyte GV Injection. Since the position of the GV in recipient oocytes is not
visible, some practice is required to obtain an 80% or better rate of success in




















depositing material in the GV of living oocytes. In some experiments, we
coinject a plasmid DNA with a GFP tag such that the oocyte’s membrane is
visibly green under fluorescence, and the oocytes not showing this GFP are
excluded from subsequent analysis. The chance of a second DNA being de-
posited in the same part of the GV as the first DNA is not always achieved,
and the gel-like consistency of the GV means that the two DNAs do not
always move to the same part of the GV. The variability of luminometer
values for the two FF or R fluorescences depends on how effectively the
second GV injection was deposited in the same part of the GV as the first
injection. Moreover, the values for oocytes with or without a second DNA
injection are sufficiently large that the conclusions are not affected by this
uncertainty (see Fig. 6).
Data Availability. All the data used in this manuscript has been mentioned in
the text. The data that support the findings of this study are available from
J.B.G. upon reasonable request.
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